
==== Front
Br J Surg
Br J Surg
bjs
The British Journal of Surgery
0007-1323
1365-2168
Oxford University Press UK

10.1093/bjs/znae230
znae230
Short Report
AcademicSubjects/MED00910
Bjs/6
Bjs/9
Prospective multicentre observational study evaluating acute lower limb ischaemia (PROMOTE-ALI)
Gratl Alexandra Department of Vascular Surgery, Medical University of Innsbruck, Innsbruck, Austria

Busch Albert Division of Vascular and Endovascular Surgery, Department of Visceral, Thoracic and Vascular Surgery, Technical University of Dresden and University Hospital Carl-Gustav Carus, Dresden, Germany

Caradu Caroline Department of Vascular Surgery, Bordeaux University Hospital, Bordeaux, France

Doukas Panagiotis Department of Vascular Surgery, European Vascular Centre Aachen-Maastricht, RWTH Aachen, Aachen, Germany

Noronen Katariina Department of Vascular Surgery, Helsinki University Central Hospital, Helsinki, Finland

Predenciuc Alexandru Division of Vascular Surgery, Institute of Emergency Medicine, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova

Tran Lan Department of Vascular Surgery, University Medical Centre Amsterdam, Amsterdam, The Netherlands

Zielasek Christian Department of Vascular Surgery, Inselspital, Bern University Hospital, Bern, Switzerland

Zlatanovic Petar Clinic for Vascular and Endovascular Surgery, University Clinical Centre of Serbia, Belgrade, Serbia

https://orcid.org/0000-0002-7200-4145
Enzmann Florian K Department of Vascular Surgery, Medical University of Innsbruck, Innsbruck, Austria

European Vascular Research Collaborative (EVRC) Leinweber Maria-Elisabeth
Matia Ivan
Duprey Ambroise
Massiot Nicolas
Guimo François
Chakfé Nabil
Kuntz Salome
Schwein Adeline
Sénémaud Jean
Castier Yves
Dehina Leila
Millon Antoine
Pouhin Alexandre
Touma Joseph
Nasr Bahaa
Settembre Nicla
Maurel Blandine
Jayet Jeremie
Coscas Raphael
Lareyre Fabien
Gombert Alexander
Oberhuber Alexander
Werra Ursula
Frese Jan Paul Bernhard
Wagenhäuser Markus
Berczeli Marton
Szeberin Zoltan
Casian Dumitru
Jongkind Vincent
Teraa Martin
Kukulski Leszek
Budakov Nebojsa
Stepanovic Nemenja
Karelis Angelos
Weiss Salome
Chaikhouni Basel
Béguin Mathieu
Menges Anna-Leonie
Wyss Thomas
Darwish Mariam
Meecham Lewis
Mazumdar Eshan
Powezka Katarzyna

Correspondence to: Florian K Enzmann, Department of Vascular Surgery, Medical University of Innsbruck, Anichstraße 35, Innsbruck, 6020, Austria (e-mail: Florian.enzmann@i-med.ac.at)
Members of the European Vascular Research Collaborative are co-authors of this study and are listed under the heading Collaborators.

9 2024
17 9 2024
17 9 2024
111 9 znae23014 7 2024
19 8 2024
© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
==== Body
pmcIntroduction

Acute lower limb ischaemia (ALI) constitutes a major challenge for vascular specialists. However, clinical guidelines on the management of ALI suggest that robust contemporary data on treatment and outcomes to inform optimal management are lacking1. ALI has been previously related to short-term limb loss rates as high as 42% and in-hospital mortality rates up to 20%2–4.

Endovascular therapy (EVT) is an alternative to open surgical revascularization (OS), as described in four RCTs performed in the 1990s5–8. A Cochrane review of these RCTs showed no evidence in favour of either technique in terms of limb salvage or survival9. Contemporary data from the USA suggested no difference in survival and limb salvage outcomes between percutaneous and surgical thrombectomy10. In contrast, a large registry from Sweden reported that EVT may reduce mortality compared with OS, without any impact on rates of amputation11. An alternative revascularization approach is to combine EVT and surgical techniques in hybrid procedures; however, data on hybrid procedures are also scarce1,12,13.

The aim of this study was to perform a multicentre prospective analysis of patients presenting with ALI to evaluate the current treatment strategies and outcomes for ALI patients, with a special focus on risk factors for loss of amputation-free survival (AFS).

Methods

A prospective multicentre observational study evaluating patients with ALI (PROMOTE-ALI) was conducted by the European Vascular Research Collaborative (EVRC) and registered at ClinicalTrials.gov (NCT05138679). The recruitment interval was from December 2021 to May 2023 and the recorded clinical parameters were based on a Delphi consensus14. Patients suffering from unilateral or bilateral ALI according to Rutherford grading were eligible15. The primary endpoint was AFS 90 days after the diagnosis of ALI. The detailed study protocol was previously published16. Details regarding methods are available in the Supplementary Methods.

Results

Some 705 patients presenting with ALI were recruited from 36 vascular centres in 12 European countries (Table S1). Chronic kidney disease (P = 0.028), smoking (P = 0.038), and pre-existing direct oral anticoagulation (P = 0.020) were significantly associated with loss of 90-day AFS. The high number of active COVID-19 infections (131 patients, 18.6%) at the time of ALI diagnosis was not associated with inferior AFS (P = 0.086). Details regarding demographics and co-morbidities are listed in Table S2.

Aetiology and clinical status at diagnosis

ALI presenting after prior revascularization (OS and EVT) was the most common aetiology (219 patients, 31.1%), followed by native artery thrombosis (197 patients, 27.9%) and embolic events (194 patients, 27.5%). Rutherford grade III ALI at admission (P < 0.001) and heparinization at the time of diagnosis (P = 0.041) were both associated with reduced 90-day AFS (Table S3).

Most cases of ALI were localized in the femoral (443 patients, 62.8%) or popliteal (364 patients, 51.6%) arteries. ALI due to arterial occlusion affecting the aorta (P = 0.001) or crural vessels (P = 0.001) exhibited the strongest correlation with reduced 90-day AFS (Fig. S1). In 329 patients (46.7%), only one arterial segment was occluded and, in 259 (36.7%) patients, two anatomical segmental levels were affected. Patients with three or more levels of occlusion (117 patients, 16.6%) had significantly worse 90-day AFS (P < 0.001).

Treatment

A total of 675 patients (95.7%) underwent revascularization and the remaining patients were treated conservatively (25 patients) or with primary amputation (5 patients). OS was the most common treatment modality, followed by hybrid procedures and EVT. A Kaplan–Meier analysis of the three groups did not show any significant differences regarding 90-day AFS (OS 83.2%, EVT 86.6%, and hybrid 81.6%; log rank P = 0.709). Revascularized patients had significantly higher 90-day AFS (83.5% versus 54.7%; P < 0.001). Details regarding performed procedures are shown in Table 1.

Table 1 Procedural data

Variables	Overall
(n = 705)	Patients with 90-day AFS
(n = 595)	Patients without 90-day AFS
(n = 110)	P	
No revascularization	30	19	11	0.001	
 Primary amputation	5	–	5	–	
Revascularization	675 (95.7)	576 (96.8)	99 (90)	0.001	
 Open surgery only	393 (55.7)	334 (56.1)	59 (54)	0.629	
 Endovascular only	135 (19.1)	119 (20.0)	16	0.182	
 Hybrid procedure	147 (20.8)	123 (20.7)	24	0.786	
Detailed procedures*					
 Embolectomy	427 (60.1)	359 (60.3)	68 (62)	0.771	
 Endarterectomy	116 (16.5)	99 (17)	17	0.758	
 Prosthetic bypass	80 (11)	65 (11)	15	0.411	
 Vein bypass	58 (8)	50 (8)	8	0.692	
 PTA only	77 (11)	65 (11)	12	0.996	
 PTA and stenting	137 (19.4)	120 (20.2)	17 (15.5)	0.252	
 Aspiration thrombectomy	75 (11)	67 (11)	8	0.213	
 Thrombolysis	84 (12)	71 (12)	13	0.973	
 Atherectomy	18	18	0	0.065	
Compartment syndrome	73 (10)	58 (10)	15	0.219	
Fasciotomy	132 (18.7)	106 (17.8)	26	0.151	
 During initial procedure	110 (15.6)	87 (15)	23	0.095	
 As a secondary procedure	22	19	3	0.797	
Values are n (%). *Multiple procedures possible. AFS, amputation-free survival; PTA, percutaneous transluminal angioplasty.

Clinical outcome

Overall AFS was 86.0% at 30 days and 82.4% at 90 days. A total of 66 major amputations (9.4%) were performed and 55 (7.8%) patients died after 90 days. The most frequent cause of death was multiple organ failure (32 patients, 4.5%). Details regarding primary and secondary endpoints, including clinical outcomes, are shown in Table S4.

Risk factors for loss of amputation-free survival

Factors significantly associated with loss of 90-day AFS were included in a multivariable model, highlighting acute kidney injury, no revascularization, Rutherford grade III ALI, and three or more levels of arterial occlusion as independent risk factors for loss of 90-day AFS (Table 2).

Table 2 Risk factors for loss of amputation-free survival at 90 days

Risk factor	Univariable analysis	Multivariable analysis*	
HR (95% c.i.)	P	HR (95% c.i.)	P	
Acute kidney injury†	6.68 (4.40,10.13)	<0.001	5.21 (3.40,8.00)	<0.001	
Additional revascularization	1.58 (1.00,2.50)	0.051	–	–	
Blood transfusion	2.41 (1.29,4.49)	0.006	1.29 (0.67,2.47)	0.450	
CKD (eGFR <30 ml/min/1.73 m2)	2.00 (1.08,3.74)	0.028	–	–	
DOACs	1.65 (1.08,2.53)	0.020	–	–	
Heparin at diagnosis	1.55 (1.01,2.37)	0.043	–	–	
No revascularization	3.56 (1.91,6.65)	<0.001	2.73 (1.41,5.29)	0.003	
Occlusion aorta	3.29 (1.81,6.00)	<0.001	1.89 (0.96,3.73)	0.067	
Occlusion crural	1.88 (1.27,2.79)	0.002	1.36 (0.85,2.17)	0.197	
Re-intervention due to bleeding	2.14 (0.99,4.59)	0.052	–	–	
Rutherford grade III ALI	3.07 (1.97,4.80)	<0.001	2.19 (1.36,3.51)	0.001	
Smoking (active and previous)	1.58 (1.03,2.45)	0.038	–	–	
Traumatic ALI	4.03 (1.28,12.72)	0.017	–	–	
Three or more levels of occlusion	2.93 (1.97,4.35)	<0.001	1.94 (1.18,3.16)	0.008	
Wound infection	1.74 (0.97,3.10)	0.062	–	–	
Wound re-intervention	1.79 (1.08,2.97)	0.024	–	–	
*Variables identified in univariable analysis (P ≤ 0.010) were included in a multivariable Cox proportional hazards model for associations with loss of amputation-free survival at 90 days. †Injury or higher—according to the RIFLE (risk, injury, and failure, sustained loss and end-stage kidney disease) criteria. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate (calculated using the CKD-EPI equation); DOACs, direct oral anticoagulants; ALI, acute lower limb ischaemia.

Discussion

Despite ALI representing a common vascular emergency, high-quality contemporary data on the presentation, treatment, and outcomes are scarce. The present study stands as the largest prospective cohort on ALI to date. Consistent with the findings of the present study, previous research reported 30-day AFS rates between 82.1% and 87.5%3,11. The impact of different revascularization techniques on AFS is controversial. Whereas the present study did not identify the type of procedure as a significant factor, previous studies suggested that the choice of revascularization technique may impact the likelihood of major amputation3,11. Notably, preoperative and postoperative parameters, such as Rutherford grade III ALI, three or more levels of arterial occlusion, and acute kidney injury, significantly affected AFS in the present study.

Over recent decades, studies have suggested a reduction in the proportion of OS procedures with more favourable results after EVT3,11,17,18. Interestingly, the present study revealed a higher-than-expected percentage of patients exclusively treated with OS. Nonetheless, the present study was unable to demonstrate any superiority in terms of AFS of OS, EVT, or hybrid procedures.

Despite guideline recommendations advocating for heparinization of patients awaiting revascularization, it was performed for fewer than two-thirds of patients in the present study.

The revised version of the Rutherford grading system for ALI, though widely utilized, demonstrated limitations in the present study. Rutherford grade III ALI is conventionally defined as irreversible ischaemia predictably requiring major amputation15 and it was one of the strongest risk factors for loss of AFS in the present study. In total, 9.9% of patients were diagnosed with Rutherford grade III ALI at the time of inclusion, which is remarkably high compared with previous data11. Surprisingly, two-thirds of those patients ultimately survived without undergoing major amputation. The role of the Rutherford grading system in patient evaluation and decision-making may be limited and its intended predictive capability regarding clinical outcomes is debatable. Despite its widespread application since 1997, the clinical performance and ability to provide a prognosis have never been validated1.

Furthermore, acute kidney injury19 emerged as an independent risk factor for loss of AFS, highlighting the importance of post-procedural surveillance and optimized medical therapy to improve care and outcomes for the ALI population20.

This is the largest prospective study on ALI. No discernible difference could be detected in 90-day AFS between OS, EVT, and hybrid procedures. Rutherford grade III ALI, multi-level arterial occlusions, no revascularization, and acute kidney injury were identified as major risk factors for amputation or mortality within 90 days after ALI diagnosis. This highlights the need for individualized risk- and lesion-adapted revascularization strategies, along with diligent post-procedural surveillance to mitigate adverse events and improve limb salvage and survival in ALI patients.

Collaborators

European Vascular Research Collaborative (EVRC)

Maria-Elisabeth Leinweber (Department of Vascular Surgery, Clinic Ottakring, Vienna, Austria); Ivan Matia (Department of Cardiac and Vascular Surgery, Clinic of Floridsdorf, Vienna, Austria); Ambroise Duprey (Department of Vascular Surgery and Angiology, Reims University Hospital Centre, France); Nicolas Massiot (Department of Vascular Surgery and Angiology, Reims University Hospital Centre, France); François Guimo (Department of Vascular Surgery and Angiology, Reims University Hospital Centre, France); Nabil Chakfé (Department of Vascular Surgery, University Hospital of Strasbourg, France); Salome Kuntz (Department of Vascular Surgery, University Hospital of Strasbourg, France); Adeline Schwein(Department of Vascular Surgery, University Hospital of Strasbourg, France); Jean Sénémaud (Department of Vascular Surgery, Bichat Hospital Paris, France); Yves Castier (Department of Vascular Surgery, Bichat Hospital Paris, France); Leila Dehina (Department of Vascular and Endovascular Surgery, Hospices Civils de Lyon, France); Antoine Millon (Department of Vascular and Endovascular Surgery, Hospices Civils de Lyon, France); Alexandre Pouhin (Department of Vascular Surgery, Dijon University Hospital, France); Joseph Touma (Department of Vascular Surgery, Henri Mondor University Hospital, France); Bahaa Nasr (Department of Vascular and Endovascular Surgery, Brest University Hospital, France); Nicla Settembre (Department of Vascular and Endovascular Surgery, Nancy University Hospital, Université de Lorraine, France); Blandine Maurel (Department of Vascular and Endovascular Surgery, Nantes University Hospital, France); Jeremie Jayet (Department of Vascular and Interventional Surgery, Ambroise Paré University Hospital, Paris, France); Raphael Coscas (Department of Vascular and Interventional Surgery, Ambroise Paré University Hospital, Paris, France); Fabien Lareyre (Department of Vascular Surgery and Vascular Medicine, Hospital of Antibes, France); Alexander Gombert (Department of Vascular Surgery, European Vascular Centre Aachen-Maastricht, RWTH Aachen, Germany); Alexander Oberhuber (Department of Vascular and Endovascular Surgery, University Hospital of Muenster, Germany); Ursula Werra (Department of Vascular and Endovascular Surgery, University Hospital Cologne, University of Cologne, Germany); Jan Paul Bernhard Frese (Department of Vascular Surgery, Charité-Universitätsmedizin Berlin, Germany); Markus Wagenhäuser (Department of Vascular and Endovascular Surgery, University Hospital of Duesseldorf, Germany); Marton Berczeli (Heart and Vascular Center, Semmelweis University Hospital, Hungary); Zoltan Szeberin (Heart and Vascular Center, Semmelweis University Hospital, Hungary); Dumitru Casian (Department of General Surgery, Institute of Emergency Medicine, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova); Vincent Jongkind (Department of Vascular Surgery, University Medical Center Amsterdam, Netherlands); Martin Teraa (Department of Vascular Surgery, University Medical Center Utrecht, Netherlands); Leszek Kukulski (Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland); Nebojsa Budakov (Clinic for Vascular and Endovascular Surgery, Clinical Center Novi Sad, Serbia); Nemenja Stepanovic (Clinic of Vascular Surgery, Clinical Center Nis, Serbia); Angelos Karelis (Vascular Center, Department of Thoracic Surgery and Vascular Diseases, Skåne University Hospital, Malmö, Sweden); Salome Weiss (Department of Vascular Surgery, University Hospital of Bern, Switzerland); Basel Chaikhouni (Department of Vascular Surgery, University Hospital of Bern, Switzerland); Mathieu Béguin (Department of Vascular Surgery, University Hospital of Bern, Switzerland); Anna-Leonie Menges (Department of Vascular Surgery, University Hospital Zurich, Switzerland); Thomas Wyss (Department of Interventional Radiology and Vascular Surgery, Kantonsspital Winterthur, Switzerland); Mariam Darwish (Department of Vascular Surgery, University Hospital Wales, Cardiff, UK); Lewis Meecham (Department of Vascular Surgery, University Hospital Wales, Cardiff, UK); Eshan Mazumdar (Department of Vascular Surgery, University Hospital Wales, Cardiff, UK); Katarzyna Powezka (Department of Vascular Surgery, NHS Lothian, Scotland, UK).

Supplementary Material

znae230_Supplementary_Data

Funding

The authors have no funding to declare.

Author contributions

Alexandra Gratl (Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Writing—original draft), Albert Busch (Conceptualization, Data curation, Investigation, Project administration, Resources, Writing—review & editing), Caroline Caradu (Conceptualization, Data curation, Formal analysis, Investigation, Project administration, Supervision, Validation, Visualization, Writing—review & editing), Panagiotis Doukas (Formal analysis, Investigation, Methodology, Project administration, Software, Validation, Writing—original draft, Writing—review & editing), Katariina Noronen (Formal analysis, Investigation, Methodology, Project administration, Resources, Validation, Writing—review & editing), Alexandru Predenciuc (Data curation, Formal analysis, Project administration, Resources, Validation, Writing—review & editing), Lan Tran (Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Resources, Software, Writing—review & editing), Christian Zielasek (Data curation, Investigation, Project administration, Resources, Validation, Writing—review & editing), Petar Zlatanovic (Conceptualization, Data curation, Formal analysis, Investigation, Project administration, Validation, Writing—review & editing), Florian K. Enzmann (Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing—original draft, Writing—review & editing), and the European Vascular Research Collaborative (Data curation, Investigation, Validation, Writing—review & editing)

Disclosure

The authors declare no conflict of interest.

Supplementary material

Supplementary material is available at BJS online.

Data availability

Research data supporting this publication are available directly from the corresponding author on reasonable request.
==== Refs
References

1 Björck  M, Earnshaw  JJ, Acosta  S, Bastos Gonçalves  F, Cochennec  F, Debus  ES  et al  Editor’s Choice—European Society for Vascular Surgery (ESVS) 2020 clinical practice guidelines on the management of acute limb ischaemia. Eur J Vasc Endovasc Surg  2020;59 :173–218 31899099
2 Baril  DT, Patel  VI, Judelson  DR, Goodney  PP, McPhee  JT, Hevelone  ND  et al  Outcomes of lower extremity bypass performed for acute limb ischemia. J Vasc Surg  2013;58 :949–956 23714364
3 Baril  DT, Ghosh  K, Rosen  AB. Trends in the incidence, treatment, and outcomes of acute lower extremity ischemia in the United States Medicare population. J Vasc Surg  2014;60 :669–77.e2 24768362
4 Genovese  EA, Chaer  RA, Taha  AG, Marone  LK, Avgerinos  E, Makaroun  MS  et al  Risk factors for long-term mortality and amputation after open and endovascular treatment of acute limb ischemia. Ann Vasc Surg  2016;30 :82–92 26560838
5 Cragg  AH, Smith  TP, Corson  JD, Nakagawa  N, Castaneda  F, Kresowik  TF  et al  Two urokinase dose regimens in native arterial and graft occlusions: initial results of a prospective, randomized clinical trial. Radiology  1991;178 :681–686 1994402
6 Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg  1994;220 :251–266, discussion 266–268 8092895
7 Ouriel  K, Shortell  CK, DeWeese  JA, Green  RM, Francis  CW, Azodo  MV  et al  A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg  1994;19 :1021–1030 8201703
8 Braithwaite  BD, Buckenham  TM, Galland  RB, Heather  BP, Earnshaw  JJ. Prospective randomized trial of high-dose bolus versus low-dose tissue plasminogen activator infusion in the management of acute limb ischaemia. Thrombolysis Study Group. Br J Surg  1997;84 :646–650 9171752
9 Darwood  R, Berridge  DC, Kessel  DO, Robertson  I, Forster  R. Surgery versus thrombolysis for initial management of acute limb ischaemia. Cochrane Database Syst Rev  2018; (8) CD002784 30095170
10 Jarosinski  M, Kennedy  JN, Khamzina  Y, Alie-Cusson  FS, Tzeng  E, Eslami  M  et al  Percutaneous thrombectomy for acute limb ischemia is associated with equivalent limb and mortality outcomes compared with open thrombectomy. J Vasc Surg  2024;79 :1151–1162.e3 38224861
11 Grip  O, Wanhainen  A, Michaëlsson  K, Lindhagen  L, Björck  M. Open or endovascular revascularization in the treatment of acute lower limb ischaemia. Br J Surg  2018;105 :1598–1606 30043994
12 Konstantinou  N, Argyriou  A, Dammer  F, Bisdas  T, Chlouverakis  G, Torsello  G  et al  Outcomes after open surgical, hybrid, and endovascular revascularization for acute limb ischemia. J Endovasc Ther  2023; DOI: 10.1177/15266028231210232  [Epub ahead of print]
13 de Donato  G, Setacci  F, Sirignano  P, Galzerano  G, Massaroni  R, Setacci  C. The combination of surgical embolectomy and endovascular techniques may improve outcomes of patients with acute lower limb ischemia. J Vasc Surg  2014;59 :729–736 24342067
14 Behrendt  CA, Björck  M, Schwaneberg  T, Debus  ES, Cronenwett  J, Sigvant  B  et al  Editor’s Choice—Recommendations for registry data collection for revascularisations of acute limb ischaemia: a Delphi consensus from the International Consortium of Vascular Registries. Eur J Vasc Endovasc Surg  2019;57 :816–821 31128987
15 Rutherford  RB, Baker  JD, Ernst  C, Johnston  KW, Porter  JM, Ahn  Set al  Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg  1997;26 :517–538 9308598
16 Gratl  A, European Vascular Research Collaborative (EVRC). Study protocol of a prospective multicenter observational study evaluating acute lower limb ischemia. J Surg Res  2023;282 :280–284 36347128
17 Kolte  D, Kennedy  KF, Shishehbor  MH, Mamdani  ST, Stangenberg  L, Hyder  ON  et al  Endovascular versus surgical revascularization for acute limb ischemia: a propensity-score matched analysis. Circ Cardiovasc Interv  2020;13 :e008150 31948292
18 Stoklasa  K, Sieber  S, Naher  S, Bohmann  B, Kuehnl  A, Stadlbauer  T  et al  Patients with acute limb ischemia might benefit from endovascular therapy—A 17-year retrospective single-center series of 985 patients. J Clin Med  2023;12 :5462 37685530
19 Bellomo  R, Ronco  C, Kellum  JA, Mehta  RL, Palevsky  P, Acute Dialysis Quality Initiative Workgroup. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care  2004;8 :R204–R212 15312219
20 Zlatanovic  P, Koncar  I, Dragas  M, Ilic  N, Sladojevic  M, Mutavdzic  P  et al  Combined impact of chronic kidney disease and contrast induced acute kidney injury on long-term outcomes in patients with acute lower limb ischaemia. Eur J Vasc Endovasc Surg  2018;56 :78–86 29636253
